Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any primary mitochondrial disease in which the cause of the disease is monoallelic or biallelic variants in the OPA1 gene. While optic atrophy is present in most affected cases, OPA1 is a mitochondrial protein and thus features of this disease include abnormal mitochondrial morphology and multiple mitochondrial DNA deletions, and can affect other organ systems and. Extraocular features can include progressive sensorineural hearing impairment, cognitive impairment, peripheral neuropathy, myopathy, ragged-red muscle fibers, and exercise-induced lactic acidemia, while additional ocular features can include progressive visual loss, central scotoma, and color vision abnormalities.
Biomarker and diagnostic research for OPA1-related optic atrophy with or without extraocular features has been reported in the published literature.
No clinical trials have been registered for OPA1-related optic atrophy with or without extraocular features.
174 publications have been identified in PubMed for OPA1-related optic atrophy with or without extraocular features. Kisho has analyzed 123 by research type. Research spans Review / Meta-Analysis (27%), Epidemiology / Natural History (26%), and Case Report / Case Series (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 33 | 27% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 6:50 AM UTC
Common questions about OPA1-related optic atrophy with or without extraocular features
Disease patterns and progression | 32 | 26% |
Patient case studies | 22 | 18% |
Testing and diagnosis research | 16 | 13% |
Laboratory research | 13 | 11% |
Clinical study results | 6 | 5% |
New treatment approaches | 1 | 1% |
Muni I (2026). [PMID: 34033320](https://pubmed.ncbi.nlm.nih.gov/34033320/). *Unknown Journal*. [Case Report / Case Series]
Schrittwieser J (2026). [PMID: 41944540](https://pubmed.ncbi.nlm.nih.gov/41944540/). *Invest Ophthalmol Vis Sci*. [Epidemiology / Natural History]
Niaudet C (2026). [PMID: 41271176](https://pubmed.ncbi.nlm.nih.gov/41271176/). *Radiother Oncol*. [Review / Meta-Analysis]
Khanna RK (2026). [PMID: 42061574](https://pubmed.ncbi.nlm.nih.gov/42061574/). *Surv Ophthalmol*. [Review / Meta-Analysis]
Hamasaki I (2026). [PMID: 42220668](https://pubmed.ncbi.nlm.nih.gov/42220668/). *Cureus*. [Case Report / Case Series]
Elhusseiny AM (2026). [PMID: 41431351](https://pubmed.ncbi.nlm.nih.gov/41431351/). *Curr Opin Ophthalmol*. [Review / Meta-Analysis]
Yanai R (2026). [PMID: 41898347](https://pubmed.ncbi.nlm.nih.gov/41898347/). *Biomedicines*. [Epidemiology / Natural History]
Falsaperla R (2026). [PMID: 41091952](https://pubmed.ncbi.nlm.nih.gov/41091952/). *J Child Neurol*. [Review / Meta-Analysis]
Chua C (2026). [PMID: 42170682](https://pubmed.ncbi.nlm.nih.gov/42170682/). *JBMR Plus*. [Case Report / Case Series]
Petrov KB (2026). [PMID: 41782526](https://pubmed.ncbi.nlm.nih.gov/41782526/). *Zh Nevrol Psikhiatr Im S S Korsakova*. [Review / Meta-Analysis]